We are inspired by curiosity, science, and, most importantly, patients, combining a creative approach with our relentless drive to transform the way we treat disease.
EMD Serono, a business of Merck Healthcare KGaA, Darmstadt, Germany is a leading science and technology company, operates across healthcare, life science, and performance materials. Around 52,000 employees work to make a positive difference in millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices — the company is everywhere.
Tepotinib is currently approved for treating advanced or metastatic METex14 NSCLC in many countries globally, including the United States and the European Union, and is under clinical investigation in various other countries. The safety and efficacy of tepotinib must be investigated following the respective national regulations and laws. There is no guarantee that tepotinib will be approved in the sought-after indication by the health authority in your country.
©2024 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved. EMD Serono is the healthcare business of Merck KGaA, Darmstadt, Germany, in the US and Canada.
Use and access of this site are subject to the terms and conditions set out in our Legal Statement and Privacy Policy.
This site is intended for US residents only.
US-TEP-00809 April 2024
US-TEP-00380 August 2021